Home Cart Sign in  
Chemical Structure| 625-51-4 Chemical Structure| 625-51-4

Structure of 625-51-4

Chemical Structure| 625-51-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 625-51-4 ]

CAS No. :625-51-4
Formula : C3H7NO2
M.W : 89.09
SMILES Code : CC(NCO)=O
MDL No. :MFCD00014417
InChI Key :HWJHZLJIIWOTGZ-UHFFFAOYSA-N
Pubchem ID :69365

Safety of [ 625-51-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 625-51-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 6
Num. arom. heavy atoms 0
Fraction Csp3 0.67
Num. rotatable bonds 2
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 20.7
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

49.33 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.88
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-1.05
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.93
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.25
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.8
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.63

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

0.4
Solubility 224.0 mg/ml ; 2.52 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

0.5
Solubility 283.0 mg/ml ; 3.18 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.0
Solubility 89.5 mg/ml ; 1.0 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.59 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.0

Application In Synthesis of [ 625-51-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 625-51-4 ]

[ 625-51-4 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 60-35-5 ]
  • [ 50-00-0 ]
  • [ 625-51-4 ]
YieldReaction ConditionsOperation in experiment
With potassium hydroxide; In 1,4-dioxane; water; at 25 - 70℃; Add the compound of formula (H) (5.62 mmol)And KOH (0.66mmol) in 20mL H2O / dioxane (1: 3v / v) mixed solution,To the above mixed solution was added formaldehyde (35% aqueous solution, 8.43mmol),The reaction solution was reacted at 70 C for 5 min, and then cooled to 25 C and stirred overnight.Adjust the pH to 7 with 1N HCl,Concentrated under reduced pressure. The residue was dissolved with acetone,Dry over anhydrous sodium sulfate, filter, and concentrate,To a compound of formula (G),Used directly in the next step.
  • 2
  • [ 4437-65-4 ]
  • [ 625-51-4 ]
  • <i>N</i>-[(4-methyl-[2]quinolylmercapto)-methyl]-acetamide [ No CAS ]
  • 3
  • [ 67-56-1 ]
  • [ 625-51-4 ]
  • [ 22480-52-0 ]
  • 4
  • [ 88-04-0 ]
  • [ 625-51-4 ]
  • [ 100129-50-8 ]
  • 5
  • [ 700-96-9 ]
  • [ 625-51-4 ]
  • [ 33868-83-6 ]
  • 6
  • [ 625-51-4 ]
  • [ 106-48-9 ]
  • [ 89479-06-1 ]
  • 7
  • [ 625-51-4 ]
  • [ 107-06-2 ]
  • [ 79-39-0 ]
  • [ 98336-87-9 ]
  • 8
  • [ 625-51-4 ]
  • [ 135-19-3 ]
  • [ 68549-28-0 ]
  • 9
  • [ 625-51-4 ]
  • [ 79-16-3 ]
  • 10
  • [ 625-51-4 ]
  • [ 50-00-0 ]
  • 11
  • [ 625-51-4 ]
  • [ 1066-51-9 ]
YieldReaction ConditionsOperation in experiment
In a round-bottom f[ask equipped with a mechanica[ stirrer, a thermometer and a condenser 3.56 g (40 mmo[e) N-hydroxymethy[acetamide was mixed with 10 m[ acetonitri[e. S[ow[y, 2.20 g (10 mmo[e) P406 was added. Afterwards the reaction mixture was heated to 80 C for 1 hour. Then 0.15 g (1 mmo[e)trif[uoromethanesu[fonic acid was added and stirring was continued for 2 hours at 80 C. A[[ vo[ati[es were removed in vacuum and the residue was disso[ved in 5 m[ H20 and 10 m[ NaOH so[ution (50 %w/w in H20) and heated to 100 C for 2 hours. The obtained so[ution was ana[ysed by 31P-NMR spectroscopy. Aminomethy[phosphonic acid
  • 12
  • [ 625-51-4 ]
  • [ 44398-42-7 ]
YieldReaction ConditionsOperation in experiment
With phosphorus pentachloride; trichlorophosphate; for 2.5h;Reflux; A compound of formula (G) (3.0 mmol) was dissolved in 10 mL of POCl3,Heat to reflux and carefully add PCl5 (6.0 mmol) in portions.The reaction was refluxed for 2.5 h, and the reaction was completed by TLC.The temperature was lowered to room temperature, and the reaction solution was poured into 200 mL of ice water. The pH of the 1NNaOH solution was adjusted to neutrality, extracted with CH2Cl2, and dried over anhydrous sodium sulfate.Filtration, concentration and purification by column chromatography provided the compound of formula (F).
  • 13
  • [ 625-51-4 ]
  • [ 98022-53-8 ]
  • 15
  • [ 292638-84-7 ]
  • [ 625-51-4 ]
  • [ 3708-33-6 ]
  • 16
  • [ 292638-84-7 ]
  • [ 625-51-4 ]
  • [ 13157-53-4 ]
  • 19
  • [ 52-90-4 ]
  • [ 625-51-4 ]
  • [ 19647-70-2 ]
  • 23
  • [ 921-22-2 ]
  • [ 625-51-4 ]
  • [ 89323-22-8 ]
  • 25
  • [ 625-51-4 ]
  • [ 124-40-3 ]
  • [ 38221-31-7 ]
  • 26
  • [ 625-51-4 ]
  • [ 106-99-0 ]
  • [ 13157-55-6 ]
  • 27
  • [ 625-51-4 ]
  • [ 79-06-1 ]
  • [ 56113-44-1 ]
  • 28
  • [ 625-51-4 ]
  • [ 115-11-7 ]
  • [ 13156-30-4 ]
  • 29
  • [ 625-51-4 ]
  • [ 115-11-7 ]
  • [ 13157-54-5 ]
  • 30
  • [ 625-51-4 ]
  • [ 107-96-0 ]
  • [ 52574-08-0 ]
YieldReaction ConditionsOperation in experiment
With trifluoroacetic acid; 3-((acetamidomethyl)sulphanyl)propanoic acid (Acm) (IV.2) 3-mercaptopropanoic acid (1.64 ml; 19 mmol) is dissolved into trifluoroacetic acid (30 ml). <strong>[625-51-4]N-(hydroxymethyl)acetamide</strong> (1.6 g; 19 mmol) is next added. After stirring for 30 minutes at room temperature, TFA is evaporated off to obtain IV.2: HPLC tR 7.1 min. (linear gradient, 5-65% B, 20 min); 1H NMR (300 MHz, CDCl3, 298 K) delta 12.4 (s, COOH, 1H); 7.74 (d, NH, J=5.8 Hz, 1H); 4.34 (d, SCH2NH, J=6 Hz, 2H); 2.81 (t, CH2SCH2NH, J=6.4 Hz, 2H); 2.67 (t, CH2COOH, J=6.4 Hz, 2H); 2.1 (s, NHCOCH3, 3H); 13C NMR (300 MHz, CDCl3, 298 K) 177.45 (CO); 174.63 (CO); 41.60 (CH2); 34.37 (CH2); 25.67 (CH2); 21.46 (CH3).
  • 31
  • [ 625-51-4 ]
  • [ 121-45-9 ]
  • [ 20495-30-1 ]
  • 35
  • [ 556-50-3 ]
  • [ 625-51-4 ]
  • {2-[(Acetylamino-methyl)-amino]-acetylamino}-acetic acid [ No CAS ]
 

Historical Records

Technical Information

Categories